Zentalis Pharmaceuticals

$43.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.79 (+6.90%) As of 5:17 PM UTC today

Why Robinhood?

You can buy or sell ZNTL and other stocks, options, and ETFs commission-free!

About ZNTL

Zentalis Pharmaceuticals, Inc. Common Stock, also called Zentalis Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer.

CEO
Anthony Y. Sun
Employees
124
Headquarters
New York, New York
Founded
2014
Market Cap
1.95B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
332.87K
High Today
$44.25
Low Today
$40.32
Open Price
$40.39
Volume
367.97K
52 Week High
$61.29
52 Week Low
$23.28

ZNTL Earnings

-$2.88
-$1.92
-$0.96
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 14, Pre-Market

You May Also Like

BSPE
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure